---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-162578"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:25:10.297457+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Perspective reports 43% ORR, clean safety for [212Pb]VMT-α-NET in Phase 1/2a at AACR 2026

## Summary
- Objective response rate 43% (10/23) in Cohort 2 first half; 9 patients with deepening response since ESMO 2025.
- Safety (n=64): no DLTs, no Grade 4/5 AEs, no treatment-related discontinuations, no renal complications.
- 18 of 25 patients (72%) progression-free in Cohorts 1 and 2 first half as of March 4, 2026 data cutoff.
- Initial efficacy data from additional 23 Cohort 2 and first 8 Cohort 3 patients expected later 2026.

## SEC filing metadata
- accession: 0001193125-26-162578
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526162578/0001193125-26-162578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526162578/catx-20260418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-162578
- JSON: https://secwatch.observer/filing/0001193125-26-162578.json
- Plain text: https://secwatch.observer/filing/0001193125-26-162578.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.